All ATH shareholders need to read Endpoint News lead story today regarding Merck Pharmaceutical's $610 Million deal with a Cambridge, Mass. private biotech, Caraway Therapeutics. Sounds very much like Alterity's focus and they had better not violate our patent protections!
All ATH shareholders need to read Endpoint News lead story today...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $119.6M | |||
| Open | High | Low | Value | Volume |
| 1.1¢ | 1.1¢ | 1.0¢ | $46.86K | 4.283M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 64 | 25268416 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 18128695 | 9 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| ATH (ASX) Chart |